3692 Stock Overview
An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Hansoh Pharmaceutical Group Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$17.86 |
| 52 Week High | HK$22.80 |
| 52 Week Low | HK$11.18 |
| Beta | 0.65 |
| 11 Month Change | -15.75% |
| 3 Month Change | -3.56% |
| 1 Year Change | 22.83% |
| 33 Year Change | 2.88% |
| 5 Year Change | -28.13% |
| Change since IPO | -8.41% |
Recent News & Updates
Recent updates
Is Now The Time To Put Hansoh Pharmaceutical Group (HKG:3692) On Your Watchlist?
Nov 04
Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Aug 28Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now
Aug 07If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity
Jul 16Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Jun 24Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year
Jun 06Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
May 23Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 01Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?
Mar 28There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump
Mar 04An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued
Feb 16Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly
Dec 08Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate
Oct 12Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's
Sep 14These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Sep 09Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jul 10These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Jun 11Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jan 23Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet
Dec 01Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price
Oct 19Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Aug 28An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued
Jun 09Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing
May 19Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?
Apr 22An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued
Feb 06Shareholder Returns
| 3692 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 4.3% | -2.1% | 0.05% |
| 1Y | 22.8% | -9.4% | 11.5% |
Return vs Industry: 3692 exceeded the Hong Kong Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 3692 exceeded the Hong Kong Market which returned 11.5% over the past year.
Price Volatility
| 3692 volatility | |
|---|---|
| 3692 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 3692 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 3692's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 9,099 | Huijuan Zhong | www.hspharm.com |
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui, and Puruian tablets. The company serves pharmaceutical product distributors.
Hansoh Pharmaceutical Group Company Limited Fundamentals Summary
| 3692 fundamental statistics | |
|---|---|
| Market cap | HK$105.99b |
| Earnings (TTM) | HK$5.06b |
| Revenue (TTM) | HK$13.00b |
20.9x
P/E Ratio8.2x
P/S RatioIs 3692 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3692 income statement (TTM) | |
|---|---|
| Revenue | CN¥12.10b |
| Cost of Revenue | CN¥1.09b |
| Gross Profit | CN¥11.01b |
| Other Expenses | CN¥6.30b |
| Earnings | CN¥4.71b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.79 |
| Gross Margin | 91.01% |
| Net Profit Margin | 38.97% |
| Debt/Equity Ratio | 0.1% |
How did 3692 perform over the long term?
See historical performance and comparison